Alaunos Therapeutics, Inc. (TCRT) Stock

Alaunos Therapeutics, Inc., formerly known as ZIOPHARM Oncology, Inc., is a clinical-stage biotechnology company specializing in advanced cell therapies for oncology. Headquartered in Houston, Texas, Alaunos focuses on the development of adoptive TCR engineered T-cell therapies designed to target and treat a range of cancers.

Central to Alaunos Therapeutics' innovative pipeline is its TCR Library, currently in Phase I/II clinical trials. This library includes ten TCRs specifically engineered to target mutated KRAS, TP53, and EGFR, addressing cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company also advances hunTR, a human neoantigen T-cell receptor platform, and mbIL-15, aimed at enhancing T-cell therapy efficacy against solid tumors.

In pursuit of its mission, Alaunos Therapeutics collaborates extensively with leading institutions and organizations. These partnerships include a license agreement with PGEN Therapeutics, Inc., and research agreements with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. With its commitment to advancing innovative cancer therapies, Alaunos Therapeutics continues to push boundaries in oncology treatment, offering new hope for patients worldwide.